Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.61 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | JUN | P05412 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.56 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.56 |
| ▸ | VCP | P55072 | 1/20 | 0.55 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29881470 | 1.00 | CYP11B1 (0.61) | CYP11B1CYP11B2RAB9AMAPTNPC1 | |
| SCHEMBL457158 | 1.00 | CYP11B1 (0.61) | CYP11B1CYP11B2RAB9AMAPTNPC1 | |
| SCHEMBL6249186 | 0.92 | CYP11B1 (0.57) | CYP11B1CYP11B2RAB9AMAPTNPC1 | |
| SCHEMBL27626846 | 0.92 | CYP11B1 (0.57) | CYP11B1CYP11B2RAB9AMAPTNPC1 | |
| SCHEMBL29691639 | 0.82 | CYP11B1 (0.86) | CYP11B1CYP11B2RAB9AMAPTNPC1 | |
| SCHEMBL29691623 | 0.82 | CYP11B1 (0.86) | CYP11B1CYP11B2RAB9AMAPTNPC1 | |
| SCHEMBL6655801 | 0.81 | MKNK1 (0.49) | CYP11B1CYP11B2MAPK1MEN1LMNA | |
| SCHEMBL6655803 | 0.81 | MKNK1 (0.49) | CYP11B1CYP11B2MAPK1MEN1LMNA | |
| SCHEMBL29691514 | 0.80 | CYP11B1 (0.82) | CYP11B1CYP11B2RAB9AMAPTNPC1 | |
| SCHEMBL29691548 | 0.80 | CYP11B1 (0.82) | CYP11B1CYP11B2RAB9AMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116396272-A | Preparation method of 2, 5-dihydropyrrolidine derivative and racemic nicotine | 苏州大学 | 2023-07-07 | — | — | CN | claimed |
| WO-2023066190-A1 | COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS | NANJING IMMUNOPHAGE BIOTECH CO., LTD (CN) | 2023-04-27 | — | — | WO | claimed |
| CN-110938845-A | Plating solution for electrolytic tinning | 上村工业株式会社 | 2020-03-31 | — | — | CN | claimed |
| US-20200095698-A1 | ELECTROLYTIC TIN PLATING SOLUTION | C. UYEMURA & CO., LTD. (JP) | 2020-03-26 | — | — | US | claimed |
| WO-2012145069-A2 | MATERIALS AND METHODS USEFUL TO INDUCE CELL DEATH VIA METHUOSIS | THE UNIVERSITY OF TOLEDO (US) | 2012-10-26 | — | — | WO | claimed |
| US-20080091014-A1 | Synthetic Method and Intermediates of Rosuvastatin Calcium and Preparation Methods of Intermediates | ANHUI QUINGYUN PHARMACEUTICAL AND CHEMICAL CO., LTD. (CN) | 2008-04-17 | — | — | US | claimed |
| US-20070203138-A1 | Novel Compounds and Compositions as Cathepsin S Inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-08-30 | — | — | US | claimed |
| US-20070135386-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-14 | — | — | US | claimed |
| US-7226921-B2 | Compounds and compositions as cathepsin S inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-05 | — | — | US | claimed |
| US-7196099-B2 | Compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-27 | — | — | US | claimed |
| EP-1436255-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | Aventis Pharmaceuticals, Inc. (US) | 2004-07-14 | — | — | EP | claimed |
| US-20030199506-A1 | Novel compounds and compositions as cathepsin S inhibitors | AXYS PHARMACEUTICALS INC. | 2003-10-23 | — | — | US | claimed |
| US-20030158231-A1 | Sulfonamide compounds as protease inhibitors | Celera Corporation | 2003-08-21 | — | — | US | claimed |
| WO-2003042197-A1 | OLIGOPEPTIDES AND COMPOSITIONS CONTAINING THEM AS CATHEPSIN S INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2003-05-22 | — | — | WO | claimed |
| WO-2003024924-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2003-03-27 | — | — | WO | claimed |
| WO-2003024923-A1 | SULFONAMIDE COMPOUNDS AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2003-03-27 | — | — | WO | claimed |
| EP-1212302-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-06-12 | — | — | EP | claimed |
| WO-2001019796-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-03-22 | — | — | WO | claimed |
| US-5302608-A | Antidiabetic, anticholesterol agents; vision disorders | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-04-12 | — | — | US | claimed |
| EP-0520336-A2 | Aldehyde derivatives and their use as calpain inhibitors | FUJIREBIO Inc. (JP) | 1992-12-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203138-A1 | Novel Compounds and Compositions as Cathepsin S Inhibitors | CTSS, CTSB, CTSE | CYP11B1 3959/4885CYP11B2 4204/4885RAB9A 494/4885 |
| US-20030158231-A1 | Sulfonamide compounds as protease inhibitors | PRSS1, PRSS3, SPINT2 | CYP11B1 3357/4885CYP11B2 3427/4885RAB9A 2791/4885 |
| US-20030199506-A1 | Novel compounds and compositions as cathepsin S inhibitors | CTSS, CTSB, CTSE | CYP11B1 3741/4885CYP11B2 4270/4885RAB9A 500/4885 |
| US-20070135386-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | CTSS, CTSB, CTSE | CYP11B1 3696/4885CYP11B2 4035/4885RAB9A 448/4885 |
| US-20080091014-A1 | Synthetic Method and Intermediates of Rosuvastatin Calcium and Preparation Methods of Intermediates | KCNN4, HCN4, CACNB4 | CYP11B1 779/4885CYP11B2 674/4885RAB9A 2670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.